Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients

被引：0
|
作者：
NM Wulffraat
N Ruperto
HI Brunner
S Oliveira
Y Uziel
K Nistala
R Cimaz
MA Ferrandiz
B Flato
M Gamir
I Kone-Paut
C Gaillez
K Lheritier
K Abrams
A Martini
D Lovell
机构：
[1] PRINTO-Istituto Gaslini,
[2] UMC Utrecht,undefined
[3] PRCSG,undefined
[4] Novartis Pharma AG,undefined
[5] Novartis Pharmaceuticals Corporation,undefined
来源：
Pediatric Rheumatology | / 12卷 / Suppl 1期
关键词：
Placebo; Placebo Group; Relative Risk Reduction; Juvenile Idiopathic Arthritis Patient; Canakinumab;
D O I：
10.1186/1546-0096-12-S1-P68
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Response to Canakinumab Treatment Is Maintained in Systemic Juvenile Idiopathic Arthritis Patients.
    Wulffraat, N. M.
    Ruperto, N.
    Brunner, H. I.
    Oliveira, S.
    Uziel, Y.
    Nistala, K.
    Cimaz, R.
    Ferrandiz, M.
    Flato, B.
    Gamir, M. L.
    Kone-Paut, I.
    Gaillez, C.
    Lheritier, K.
    Abrams, K.
    Martini, A.
    Lovell, D. J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S413 - S414
  • [2] MAINTENANCE OF EFFICACY BY CANAKINUMAB TREATMENT IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS
    Wulffraat, N. M.
    Ruperto, N.
    Brunner, H. I.
    Oliveira, S.
    Uziel, Y.
    Nistala, K.
    Cimaz, R.
    Ferrandiz, M. A.
    Flato, B.
    Gamir, M. L.
    Kone-Paut, I.
    Gaillez, C.
    Lheritier, K.
    Abrams, K.
    Martini, A.
    Lovell, D. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 130 - 130
  • [3] Canakinumab Treatment Shows Maintained Efficacy in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Individual Patient Level: An Analysis of 12 Week Pooled Data
    Ravelli, A.
    Brunner, H. I.
    Ruperto, N.
    Quartier, P.
    Consolaro, A.
    Wulffraat, N. M.
    Lheritier, K.
    Gaillez, C.
    Martini, A.
    Lovell, D. J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1003 - S1003
  • [4] Canakinumab for the treatment of systemic juvenile idiopathic arthritis
    Grom, Alexei A.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (11) : 1427 - 1435
  • [5] Canakinumab for the treatment of active systemic juvenile idiopathic arthritis
    Orrock, Janet E.
    Ilowite, Norman T.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1015 - 1024
  • [6] Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis Patients Previously Exposed to Biologics
    Brunner, Hermine I.
    Ruperto, Nicolino
    Quartier, Pierre
    Constantin, Tamas
    Berkun, Yackov
    Calvo-Penedes, Inmaculada
    Erguven, Mueferet
    Goffin, Laurence
    Hofer, Michael
    Kallinich, Tilmann
    Oliveira, Sheila
    Uziel, Yosef
    Viola, Stefania
    Nistala, Kiran
    Wouters, Carine
    Leon, Karolynn
    Speziale, Antonio
    Lheritier, Karine
    Junge, Guido
    Lovell, Daniel
    Martini, Alberto
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis
    Sun, Haiying
    Van, Linh M.
    Floch, David
    Jiang, Xuemin
    Klein, Ulf R.
    Abrams, Ken
    Sunkara, Gangadhar
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (12): : 1516 - 1527
  • [8] Tapering canakinumab in systemic juvenile idiopathic arthritis
    Thorley, Jennifer
    [J]. LANCET RHEUMATOLOGY, 2020, 2 (10): : E593 - E593
  • [9] Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1423): : 65 - 66
  • [10] A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis
    Wulffraat, Nico M.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (12) : 1961 - 1967
12345